North East and North Cumbria
ICS Formulary
ICS Formulary
7 Obstetrics, Gynaecology, and urinary-tract disorders
07-03-05 Hormonal methods
| Levonorgestrel 1.5mg tablet Levonelle 1500® |
|
Second Choice
|
|
 MHRA Drug Safety Update (Sept 2016): Levonorgestrel- containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy. |
|
| Ulipristal 30mg tablet ellaOne® |
|
Formulary
|
|
 NTAG - Ulipristal (Ellaone®) for post-coital (up to 120 hours) contraception |
|
|
Links
- County Durham and Darlington Adult Bladder and Bowel formulary First Line Prescribing Guide 2023
- FSRH Standards & Guidance
- MHRA Drug Safety Update (June 2015): Intrauterine contraception: uterine perforation—updated information on risk factors
- MHRA Drug Safety Update (March 2014): St John’s wort: interaction with hormonal contraceptives, including implants
- MHRA Drug Safety Update (Sept 2016): Levonorgestrel- containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy.
- NICE CG30: Long-acting reversible contraception
- NICE NG118: Renal and ureteric stones: assessment and management
- NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management
- NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management
- North of Tyne, Gateshead and North Cumbria Urinary Continence Enablement Products and Devices Formulary Guideline (October 2024)
- NTAG - Ulipristal (Ellaone®) for post-coital (up to 120 hours) contraception
- Tees Urinary Continence Formulary February 2020